The recent approval of tirzepatide, the first dual glucose dependent insulinotropic polypeptide and GLP 1 receptor agonist, challenges the long held assumption that targeting a single hormonal pathway is sufficient for optimal metabolic control
Therefore, because neurotransmitter imbalance contributes to depressive behaviors in patients with depression as described above, the appropriate modulation of neurotransmitters in the brain is key to treating depression ( Figure 2 )
Oral Glutathione Three randomized controlled trials support the skin-lightening effect and good safety profile of topical and oral glutathione
doi:10.1002/14651858.CD010290.pub3 Paulson R
In March 2026, the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, signaling aggressive regulatory enforcement
GIP: an inconsequential incretin or not